Motexafin gadolinium

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Motexafin gadolinium
Motexafin gadolinium 3D sticks.png
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
ChEBI
Chemical and physical data
Formula C52H72GdN5O14
Molar mass 1148.403 g/mol
3D model (JSmol)
  (verify)

Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.[1]

History[edit]

On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2]

On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3]

References[edit]